A Safety and Pharmacokinetic Study of Proellex® - Full Text View

Sponsor:	Repros Therapeutics Inc.
Information provided by:	Repros Therapeutics Inc.
ClinicalTrials.gov Identifier:	NCT00619385

Purpose

This is an open-label, single-center, outpatient, unblinded, multi-dose study of the safety and pharmacokinetic properties of Proellex®. Six female subjects will each receive seven daily doses of Proellex® 100 mg, 150 mg and 200 mg in separate, rising doses. Dosing must be accomplished between menstrual periods. The first six women will complete the 100 mg visit schedule before the next six women will begin the 150 mg visit schedule. Blood will be collected at pre-dose, and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 24 and 36 (Day 7 only) hrs post-dose on Day 1 and Day 7. Subjects will be allowed to leave the clinic between the 12 and 24 hr and the 24 and 36 hr PK blood draws. Subjects will be discharged from the study after a one month follow-up visit. Safety will be assessed throughout the study.

Condition	Intervention	Phase
Healthy	Drug: Proellex	Phase I

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Control: Uncontrolled Endpoint Classification: Pharmacokinetics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Safety and Pharmacokinetic Study of 100 mg, 150 mg and 200 mg of Proellex® Taken for Seven Days by Healthy Adult Female Subjects

Further study details as provided by Repros Therapeutics Inc.:

Primary Outcome Measures:

To determine the safety and PK properties of 100 mg, 150 mg and 200 mg of Proellex® taken for seven days by healthy adult female subjects. [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]

Enrollment:	18
Study Start Date:	February 2008
Study Completion Date:	October 2008
Primary Completion Date:	September 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
A: Experimental Proellex 100 mg	Drug: Proellex Proellex 25 mg capsules, 100 mg daily for 7 days
B: Experimental Proellex 150 mg	Drug: Proellex Proellex 25 mg capsules, 150 mg daily for 7 days
C: Experimental Proellex 200 mg	Drug: Proellex Proellex 25 mg capsules, 200 mg daily for 7 days

Eligibility

Ages Eligible for Study:	18 Years to 34 Years
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Subject must be able to speak, read and understand English and be willing and able to provide written informed consent on an Institutional Review Board (IRB)-approved form prior to the initiation of any study procedures. Subject must have signed and dated a written Informed Consent Form (ICF) before undergoing any study related activities, including discontinuation of any prohibited medications
Premenopausal women aged 18 - 34 inclusive with body mass index between 18 and 35 inclusive
Women of child-bearing potential must be willing to use effective non-hormonal, double-barrier method contraception during the study period and for a minimum of 30 days after discontinuation of the study medication. Women who have had a hysterectomy will be allowed into the study
Must have a negative urine pregnancy test at screening
Able to swallow gelatin capsules
In general good health
Must have agreed to not attempt to become pregnant at any time during study participation or for 30 days thereafter
Must not have used tobacco (nicotine products) for at least two years before the study starts
Must have normal (or abnormal and clinically insignificant) laboratory values at screening
Willing to remain in the clinic for the screening visit and for the treatment visits
Available for all treatment and follow-up visits
Willing to comply with all study procedures
Additional inclusion criteria may apply

Exclusion Criteria:

Pregnant or lactating females or women who are attempting or expecting to become pregnant at any time during the study
Past or present history of experiencing any allergic reaction to the formulations administered in this study, or in the opinion of the Principal Investigator, suggests an increased potential for an adverse hypersensitivity
Any medical condition, which, in the judgment of the Principal Investigator, will prevent the subject from starting and/or completing the study
Past or present history of any significant cardiovascular, renal, hepatic disease, thrombophlebitis, thromboembolic disorders, or cerebrovascular accident requiring ongoing medical therapy or clinical intervention
A QTc interval of >450ms at screening
Subject with abnormal screening visit vital signs or clinical laboratory evaluation considered clinically significant by the Principal Investigator
Subjects with symptomatic uterine fibroids or endometriosis
Use of other oral contraceptives or hormonal treatments within 30 days of first dose of study medication
Use of a hormone-releasing intrauterine device
Subject with a history of alcohol and/or drug abuse
Known active infection of HIV, Hepatitis A, B or C
Subject who has participated in a clinical trial with investigational medication within 30 days prior to study medication administration or who plans to take an experimental drug prior to the end of 30 days after participation in this study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00619385

Locations

United States, Texas
Healthcare Discoveries Inc.
San Antonio, Texas, United States, 78209

Sponsors and Collaborators

Repros Therapeutics Inc.

Investigators

Study Director:

Andre van As, MD, PhD

Repros Therapeutics Inc.

More Information

No publications provided

Responsible Party:	Repros Therapeutics ( Andre vanAs, MD, PhD )
Study ID Numbers:	ZP-003
Study First Received:	February 11, 2008
Last Updated:	February 8, 2010
ClinicalTrials.gov Identifier:	NCT00619385 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Repros Therapeutics Inc.:

Pharmacokinetics

ClinicalTrials.gov processed this record on March 18, 2010